128 related articles for article (PubMed ID: 30774778)
1. Immunonutritional consequences of different serine-type protease inhibitors in a C57BL/6 hepatocarcinoma model.
Laparra J; Fotschki B; Haros C
Oncotarget; 2019 Jan; 10(7):760-772. PubMed ID: 30774778
[TBL] [Abstract][Full Text] [Related]
2. Plant seed protease inhibitors differentially affect innate immunity in a tumor microenvironment to control hepatocarcinoma.
Laparra JM; Haros CM
Food Funct; 2019 Jul; 10(7):4210-4219. PubMed ID: 31257391
[TBL] [Abstract][Full Text] [Related]
3. Intestinal Intervention Strategy Targeting Myeloid Cells to Improve Hepatic Immunity during Hepatocarcinoma Development.
Bouzas Muñoz A; Giménez-Bastida JA; Tejedor AG; Haros CM; Gómez de Cedrón M; Ramírez de Molina A; Laparra Llopis JM
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829862
[TBL] [Abstract][Full Text] [Related]
4. Improvement of hepatic innate immunity in chemically-injured livers to develop hepatocarcinoma by a serine type-protease inhibitors enriched extract from
Rueda Huélamo MA; Martínez Perlado A; Consoli V; García-Tejedor A; Haros CM; Laparra Llopis JM
Food Funct; 2024 Apr; 15(7):3600-3614. PubMed ID: 38469889
[TBL] [Abstract][Full Text] [Related]
5.
Laparra Llopis JM; Brown D; Saiz B
Nutrients; 2020 Jun; 12(7):. PubMed ID: 32629893
[TBL] [Abstract][Full Text] [Related]
6. A Proteomics Data Mining Strategy for the Identification of Quinoa Grain Proteins with Potential Immunonutritional Bioactivities.
Galindo-Luján R; Pont L; Sanz-Nebot V; Benavente F
Foods; 2023 Jan; 12(2):. PubMed ID: 36673481
[TBL] [Abstract][Full Text] [Related]
7. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
9. B lymphocytes limit senescence-driven fibrosis resolution and favor hepatocarcinogenesis in mouse liver injury.
Faggioli F; Palagano E; Di Tommaso L; Donadon M; Marrella V; Recordati C; Mantero S; Villa A; Vezzoni P; Cassani B
Hepatology; 2018 May; 67(5):1970-1985. PubMed ID: 29105104
[TBL] [Abstract][Full Text] [Related]
10. STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma.
Li W; Xiao J; Zhou X; Xu M; Hu C; Xu X; Lu Y; Liu C; Xue S; Nie L; Zhang H; Li Z; Zhang Y; Ji F; Hui L; Tao W; Wei B; Wang H
J Clin Invest; 2015 Nov; 125(11):4239-54. PubMed ID: 26457732
[TBL] [Abstract][Full Text] [Related]
11. Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine.
Ding YF; Wu ZH; Wei YJ; Shu L; Peng YR
J Cancer Res Clin Oncol; 2017 May; 143(5):821-834. PubMed ID: 28238064
[TBL] [Abstract][Full Text] [Related]
12. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
[TBL] [Abstract][Full Text] [Related]
13. The role of immunonutritional support in cancer treatment: Current evidence.
Prieto I; Montemuiño S; Luna J; de Torres MV; Amaya E
Clin Nutr; 2017 Dec; 36(6):1457-1464. PubMed ID: 27931879
[TBL] [Abstract][Full Text] [Related]
14. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.
Wu K; Ding J; Chen C; Sun W; Ning BF; Wen W; Huang L; Han T; Yang W; Wang C; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
Hepatology; 2012 Dec; 56(6):2255-67. PubMed ID: 22898879
[TBL] [Abstract][Full Text] [Related]
15. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice.
Lin H; Yan J; Wang Z; Hua F; Yu J; Sun W; Li K; Liu H; Yang H; Lv Q; Xue J; Hu ZW
Hepatology; 2013 Jan; 57(1):171-82. PubMed ID: 22859216
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
17. Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice.
Li X; Liu C; Ip BC; Hu KQ; Smith DE; Greenberg AS; Wang XD
J Exp Clin Cancer Res; 2015 Nov; 34():138. PubMed ID: 26560698
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of α-lipoic acid on thioacetamide-induced tumor promotion through suppression of inflammatory cell responses in a two-stage hepatocarcinogenesis model in rats.
Fujii Y; Segawa R; Kimura M; Wang L; Ishii Y; Yamamoto R; Morita R; Mitsumori K; Shibutani M
Chem Biol Interact; 2013 Sep; 205(2):108-18. PubMed ID: 23830814
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.
Garcia MG; Bayo J; Bolontrade MF; Sganga L; Malvicini M; Alaniz L; Aquino JB; Fiore E; Rizzo MM; Rodriguez A; Lorenti A; Andriani O; Podhajcer O; Mazzolini G
Mol Pharm; 2011 Oct; 8(5):1538-48. PubMed ID: 21770423
[TBL] [Abstract][Full Text] [Related]
20. Voluntary Wheel Running Reduces the Acute Inflammatory Response to Liver Carcinogen in a Sex-specific Manner.
Bay ML; Gehl J; Pedersen BK; Hojman P
Cancer Prev Res (Phila); 2017 Dec; 10(12):719-728. PubMed ID: 28951483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
